Quoin Pharmaceuticals Ltd
QNRX6.850USD
+0.030+0.44%
Horário de mercado （ET）Cotações atrasadas em 15 min
141.01MValor de mercado
PerdaP/L TTM
Mais detalhes de Quoin Pharmaceuticals Ltd Empresa
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Informações da empresa
Código da empresaQNRX
Nome da EmpresaQuoin Pharmaceuticals Ltd
Data de listagemNov 01, 1989
CEODr. Michael Myers, Ph.D.
Número de funcionários3
Tipo de títulosDepository Receipt
Fim do ano fiscalNov 01
Endereço23 Hata'as Street
CidadeKFAR SABA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal44425
Telefone97299741444
Sitehttps://quoinpharma.com/
Código da empresaQNRX
Data de listagemNov 01, 1989
CEODr. Michael Myers, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Eyal Leibovitz
Mr. Eyal Leibovitz
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Eyal Leibovitz
Mr. Eyal Leibovitz
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 26 de jul
Atualizado em: sáb, 26 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Myers (Michael)
2.93%
Carter (Denise P)
2.93%
UBS Financial Services, Inc.
1.07%
Dunn (Gordon)
0.73%
Culverwell (Anthony James)
0.49%
Other
91.86%
Investidores
Investidores
Proporção
Myers (Michael)
2.93%
Carter (Denise P)
2.93%
UBS Financial Services, Inc.
1.07%
Dunn (Gordon)
0.73%
Culverwell (Anthony James)
0.49%
Other
91.86%
Tipos de investidores
Investidores
Proporção
Individual Investor
7.08%
Investment Advisor
1.44%
Investment Advisor/Hedge Fund
0.16%
Other
91.32%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
33
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
2023Q2
28
91.62K
18.66%
+37.20K
2023Q1
30
101.74K
19.68%
+59.45K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Myers (Michael)
17.22K
2.93%
--
--
Mar 10, 2025
Carter (Denise P)
17.22K
2.93%
+1.00
+0.01%
Mar 10, 2025
UBS Financial Services, Inc.
6.27K
1.07%
+6.13K
+4507.35%
Mar 31, 2025
Dunn (Gordon)
4.32K
0.73%
--
--
Mar 10, 2025
Culverwell (Anthony James)
2.87K
0.49%
+2.86K
+31744.44%
Mar 10, 2025
Rhumbline Advisers Ltd. Partnership
1.19K
0.2%
+504.00
+73.15%
Mar 31, 2025
Raymond James Financial Services Advisors, Inc.
718.00
0.12%
--
--
Mar 31, 2025
Lido Advisors, LLC
672.00
0.11%
+672.00
--
Mar 31, 2025
Susquehanna International Group, LLP
320.00
0.05%
+320.00
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 26, 2025
Merger
20<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jul 29, 2022
Merger
12.5<1
Data
Tipo
Proporção
Mar 26, 2025
Merger
20<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Sep 23, 2021
Merger
4<1
Ver Mais
